Please login to the form below

Not currently logged in

Roche's checkpoint inhibitor Tecentriq aces lung cancer trial

Second-line therapy showed overall survival benefit irrespective of PD-L1 status

Roche has chalked up another big success for its new immuno-oncology drug Tecentriq, showing a survival benefit in a phase III trial in non-small cell lung cancer (NSCLC).

The OAK trial revealed that PD-L1 inhibitor Tecentriq (atezolizumab) improved overall survival compared to docetaxel when used as a second-line therapy for NSCLC after platinum-based chemotherapy. Crucially, the drug had a benefit regardless of whether patients' tumours tested positive for PD-L1.

Roche has already filed for approval of the checkpoint inhibitor in NSCLC, and the FDA is due to deliver a verdict on the dossier in October having already awarded the drug breakthrough status. Tecentriq was recently approved by the FDA in its first indication - bladder cancer - and has already started to make headway in the market.

The positive result could give Roche a chance to catch its rivals in the checkpoint inhibitor category - Bristol-Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab) - which are already approved for NSCLC and other cancers such as melanoma.

The oncology community is still reeling from the news that - after a string of spectacular successes in clinical trials - Opdivo failed the Checkmate-026 study as a first-line treatment for NSCLC, a result attributed to a desire to cast the patient recruitment net a little too wide.

Opdivo has been dominant in the second-line setting however thanks to the same strategy of enrolling patients regardless of PD-L1 status, whereas Merck zeroed in on patients who had higher levels of expression of the biomarker.

That resulted in a broader label for Opdivo, that could be matched by Tecentriq if the FDA approves the NSCLC indication based on the OAK population and give it a chance to compete head-to-head with Opdivo in the second-line setting.

The first-line market is shaping up quite differently. With Merck able to show a first-line benefit with its PD-L1-targeting approach in the Keynote-024 trial, it is now expected to benefit from a lead of as much as 18 months before it will have a challenger.

Roche has a phase III trial ongoing in PD-L1-selected patients which is due to generate results in 2018, along with a series of trials looking at Tecentriq plus chemotherapy in unselected NSCLC patients.

Meanwhile, BMS is now banking on a combination trial of Opdivo and its CTLA4 inhibitor Yervoy (ipilimumab) that it hopes will support their use as an all-comer therapy, regardless of PD-L1 status.

Of course, with PD-L1 testing becoming more common in the first-line setting there should be a pull-through effect for Keytruda into second-line treatment as well, lessening the advantage of Opdivo's - and possibly Tecentriq's - broader label claim.

Regardless, Roche is now poised to go head-to-head against its rivals in the marketplace, backed by its marketing muscle as a long-standing oncology player, according to analyst Tim Anderson at Bernstein.

He has raised his forecasts for Tecentriq on the strength of the OAK data, saying it could make $4.9bn in 2021 if it gets approval for NSCLC as well as colon cancer, behind Opdivo ($8.1bn) and Keytruda (6.5bn) but ahead of AstraZeneca's PD-L1 inhibitor durvalumab ($1.8bn).

Article by
Phil Taylor

2nd September 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....